Mylan N.V. (Nasdaq: MYL) today announced the U.S. launch of Memantine Hydrochloride Tablets USP, 5 mg and 10 mg, which is the generic version of Forest's Namenda ® Tablets. Mylan received final ...

A long-established Alzheimer's drug can help people with a disorder that causes them to compulsively pull at their hair or pick at their skin, a new clinical trial has concluded. Memantine ...

Allergan plc (NYSE: AGN), today announced that its subsidiaries Forest Laboratories, LLC and Forest Laboratories Holdings, Ltd., along with Adamas Pharmaceuticals, Inc., have entered into a settlement ...

The patent term for Namenda has been extended through April 10, 2015, according to Forest Laboratories. The medication is used to help treat people with Alzheimer’s disease. The patent had earlier ...

Memantine, a drug typically used to treat symptoms of Alzheimer's disease (AD), is linked to a significant reduction in symptoms of trichotillomania and skin-picking disorder, new research shows.

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...

NEW YORK, Sept 24 (Reuters) - Actavis Plc has reached an agreement with New York's attorney general to keep selling a top Alzheimer's drug for 60 days so U.S. patients will not be forced to switch to ...

New research at the University of Chicago Medicine has found that a drug commonly used to treat symptoms of Alzheimer’s disease effectively reduced symptoms of adults who experience compulsive ...

WASHINGTON -- Americans with advanced Alzheimer's disease soon can try the first treatment proved effective for late stages of the mind-robbing illness. Memantine should be on pharmacy shelves by ...

Deprescribing ChEIs/memantine can reduce the risk for ADRs and drug-drug and drug-disease interactions. It can also reduce the pill burden for patients and improve adherence to other medications, as ...

(Reuters) - The attorney general of New York filed a lawsuit against Actavis Plc and its subsidiary to stop the companies from discontinuing its Alzheimer's drug, alleging that they were trying to ...

The dementia drug memantine showed promise for improving social functioning in a small trial of youth with autism. Nine of 16 children and adolescents treated with memantine met the response criteria ...